Bio-implant Market, By Product Type (Cardiovascular Implants, Dental Implants, Spinal Bio-implants, Orthopedic Implants, Ophthalmic Implants, and Others), By Material Type (Biomaterial Metal, Ceramic, Alloys, and Polymer), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Bio-implant Market is estimated to be valued at USD 102.41 Bn in 2025 and is expected to reach USD 153.99 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6% from 2025 to 2032.
Key Takeaways
Based on Product Type, Cardiovascular Implants Segment is expected to dominate the global bio-implant market with 30.1% shares during the forecast period.
North America is expected to dominate the global bio-implant market over the forecast period with 35. 10%market share.
Market Overview
The market for bio-implants is expected to record high growth during the forecast period, on account of increasing prevalence of chronic diseases, orthopedic disorders, and increased need for complex reconstructive and restorative operations. Bio-implants—synthetic medical devices that are engineered within the human body to complement, assist, or substitute biological structures—are extensively used in orthopedics, cardiovascular, dental restoration, and neurology treatments. Growing populations of elderly people, rising incidence of lifestyle diseases, and advancements in biomaterial and 3D printing technologies are fueling the demand for bio-implants in the developed and emerging economies.
Current Events and Its Impact on Bio-implant Market
Current Events
Description and its impact
Regenerative Implant Breakthrough Drives Innovation in Biocompatible Materials
Description: In 2025, Coll Plant Biotechnologies, together with an international medical aesthetics firm, successfully 3D-bioprinted commercial-scale breast implants employing its proprietary recombinant human collagen (rhCollagen). This achievement is part of an R&D project aimed at creating tissue-regenerative bio-implants that will integrate naturally with human tissues over time. The innovation comes as a reaction to increasing fears over silicone-based implants and demands for safer, bioengineered options in reconstructive and cosmetic procedures.
Impact: Success in this project marks a turning point for the bio-implant sector towards the use of bioresorbable, tissue-compliant materials. It provides new possibilities for completely regenerative implants that minimize immune rejection and long-term complications. The innovation has the potential to revolutionize practices in breast reconstruction, soft tissue repair, and aesthetic surgery. Yet it also creates new regulatory issues since agencies will be assessing standards for safety and efficacy for implants bio fabricated. In the near term, excessive R&D and production costs could cap adoption at the premium markets, although greater scalability is expected with subsequent cost optimization.
Smart Orthopedic Implants Gain Momentum with Digital Health Integration
Description: In March 2024, Zimmer Biomet announced the commercial launch of its next-generation Persona IQ® Smart Knee Implant in partnership with Canary Medical. The implant, which received FDA clearance, features embedded sensors that continuously monitor patient activity, range of motion, and implant performance. This data is wirelessly transmitted to clinicians for remote post-operative tracking, representing a major step toward integrating digital health into orthopedic implants.
Impact: This innovation mirrors an expanding industry trend under which bio-implants are becoming smart medical devices and not merely structural solutions. Intelligent implants such as Persona IQ are transforming post-surgical care by allowing real-time monitoring, predictive analytics, and customized rehabilitation protocols. For surgeons and hospitals, this enhances clinical outcomes and minimizes readmission. Nonetheless, the integration of electronics and connectivity introduces new complexity around data security, battery life, and regulatory compliance, particularly under changing digital health regulations.
The bio-implants market boasts a robust pipeline of upcoming products being developed, due to sustained R&D efforts to enhance functionality, biocompatibility, and patient outcomes. Orthopedic implants remain the largest segment, as a number of companies have created intelligent, sensor-based joint replacements to monitor real-time information after surgery—such as Zimmer Biomet's Persona IQ and Stryker's intelligent hip technology in advanced stages of development.
Cardiovascular bio-implants are also gaining speed, with new-generation bioresorbable heart valves and stents with promising clinical trial results. Abbott and Boston Scientific are helping to deliver better long-term vascular restoration and reduce chronic inflammation.
In neurology, products in the pipeline are bioelectronic implants for epilepsy and Parkinson's disease disorders. Medtronic and NeuroPace are also aggressively broadening indications for implantable neurostimulators. Other new indications such as ophthalmic and dental implants are also experiencing innovation in materials such as graphene composites and antimicrobial coatings.
A few of the pre-clinical and early-stage products are 3D-printed patient-specific implants and tissue-engineered scaffolds, which have the potential to transform reconstructive methods. Clearances from regulators will likely accelerate as personalized medicine and digital health integration turn into a theme of implant design. Increasing global investment in regenerative medicine along with implant tracking with AI, the pipeline shows a shift towards smarter, safer, and more robust implant offerings.
Patent Landscape – Bio-Implants Market
The bio-implants industry is experiencing a surge in patents driven by advances in biomaterials, digitalization, and minimally invasive implant designs. Leading players such as Medtronic, Stryker, Zimmer Biomet, Johnson & Johnson, and Boston Scientific are driving the global patent race, especially in orthopedic, cardiovascular, and neurostimulator implants. The principal drivers of innovation are biocompatible coatings, smart sensor integration, bioresorbable biomaterials, and patient-specific implant anatomy printed through 3D printing.
Between 2020 and 2024, both the United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) have witnessed a steady rise in filings for implantable biosensors, tissue-engineered scaffolds, and drug-eluting implants. Companies are also gaining patents for AI-based post-operative monitoring systems, as the market shifts toward digital health integration. For example, Zimmer Biomet's latest patents include embedded microelectronic systems for collection of mobility information in real time in knee implants.
In emerging markets such as China and India, educational institutions and domestic innovators alike are now filing patents for low-cost, next-generation dental and spinal implants. Growing worldwide interest in personalized medicine, regulatory approval of new devices, and increased R&D spending are likely to further expand the bio-implant patent space, reinforcing the market's long-term innovation trend.
Reimbursement Scenario
NORTH AMERICA– UNITED STATES & CANADA
Reimbursement Codes and Regulations
Reimbursement for bio-implants in North America is mainly driven by three uniform coding systems
CPT Codes (Current Procedural Terminology)
Basically, classify surgeries/procedures related to bio-implants. Examples:
Knee & Hip Implants: CPT 27447 (total knee arthroplasty), CPT 27130 (total hip arthroplasty)
HCPCS Codes (Healthcare Common Procedure Coding System)
Individual implants/devices bear specific codes; some examples are:
C1776 for Joint Device implants
Justification codes for implants
Osteoarthritis of Knee: (M17.11)
Regulatory Agencies
United States - Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA)
Canada - Canadian Agency for Drugs and Technologies in Health (CADTH), Health Canada
Processes & Agencies
United States
Medicare Coverage determination is handled by CMS via National and Local Coverage Determinations (NCDs/LCDs).
Private insurers (Blue Cross Blue Shield, United Healthcare, Aetna, Cigna) follow CMS guidelines with minor differences in coverage.
Hospitals and providers typically submit directly via clearinghouses, and reimbursable figures are determined by insurers or CMS on an annual basis.
Canada
Provincial Health Authorities are responsible for reimbursement, with guidelines provided by Health Canada and CADTH.
Hospitals submit claims via province-level reimbursement systems.
Insurance Plans, Spend, and Percentage Coverage (with supporting data)
Medicare
Covers 80- 90% of bio-implant procedures on average; patient liability is 10-20%.
US Medicare implant procedure spending annually: around USD 9 billion (2022).
Medicaid
Reimburses up to 85- 95% costs (state-dependent); procedure-specific reimbursement threshold is less than private plans.
Private Insurance
Typically, 70- 90% coverage; more lavish than government-funded programs.
Implant-based procedure spending by private healthcare accounted for USD 15 billion (2022).
ASIA (China, Japan, India)
Reimbursement Codes and Regulations
China
National Medical Insurance (NMI) system has special codes for medical implants; implantable device ICD & CPT codes are almost in line with international standards.
Provincial reimbursement codes differ slightly between areas.
Japan
Reimbursement by procedure and implant under Japan National Health Insurance has fee-for-service codes under Diagnosis Procedure Combination (DPC), which is governed by Ministry of Health, Labour, and Welfare (MHLW).
India
ICD-10 is mainly used in private/government hospitals.
Reimbursement by Ayushman Bharat Yojana (National Health Insurance Scheme) and Common Procedural Codes (CPCs).
SOUTHEAST ASIA (Indonesia, Thailand, Malaysia, Singapore)
Reimbursement Codes and Regulations
Malaysia and Singapore use ICD-10 coding as well as international implant-related coding (adapted versions of CPT/HCPCS).
Thailand Universal Coverage Scheme (UCS) uses International ICD-10 & Thailand-specific reimbursement codes via National Health Security Office (NHSO).
Prescribers’ preference
Treatment Lines and Prescriber Preferences in Bio-implantation
Prescribers typically exhibit a multi-step or multi-line pattern of treatment based largely on the severity of the patient's condition, age, comorbidities, and disease or lesion characteristics. Implant selection is directly attributed to where the patient is placed along the treatment continuum. There are three main lines of treatment that are generally identified: first-line, second-line, and further treatments or salvage regimes.
First-Line Treatment Preferences
First-line bio-implants are generally favored in initial-stage diseases where minimally invasive and bio-compatible materials are highly sought after. Doctors favor implants that provide maximum biological compatibility, minimum immunogenicity, rapid recovery, and predictable results.
Examples:
Cardiovascular: Drug-eluting stents (DES) like the XIENCE (Abbott Laboratories) and SYNERGY (Boston Scientific), as they provide safe biocompatible coatings along with medication-releasing features.
Orthopedic: Bio-absorbable pins and screws (companies such as Arthrex or Smith & Nephew) are indicated for ligament fixation and joint reconstruction procedures since they have the ability to degrade naturally with time, which facilitates healing.
Preferred Adjunctive Medications at this Stage
Prescribers often supplement these implants with preoperative prophylactic antibiotics such as Cefazolin (Ancef) to reduce the risk of infection. Anti-inflammatory medications like ibuprofen or celecoxib (Celebrex) and anticoagulants such as rivaroxaban (Xarelto) for preventing clots after surgery are prevalent during this phase.
Second-Line Treatment Preferences
Conditions that advance to the second-line intervention are usually those not well handled by initial therapy or implants that develop complications. In such a case, prescribers opt for advanced bio-implants tailored specifically for the more complicated stages, usually featuring a more robust biomechanical reinforcement and higher tolerance against rejection.
Examples
Orthopedic: Titanium-based implants like DePuy Synthes (Johnson & Johnson) artificial joints and Infuse Bone Graft by Medtronic, selected for their mechanical strength, biocompatibility, and established clinical effectiveness in demanding surgical situations.
Dental: Nobel Biocare and Straumann dental implants are preferred once initial conservative measures (like crowns or bridges) fail to satisfactorily restore tooth function or periodontal health.
Preferred Adjunctive Medications at this Stage
Second-line therapy requires more potent antibiotics to control possible infections and inflammatory processes. Therefore, broad-spectrum antibiotics such as amoxicillin-clavulanate (Augmentin) and newer NSAIDs or opioid analgesics, for example, oxycodone (OxyContin), can be used in the control of severe postoperative pain.
Subsequent or Salvage Treatment Preferences
In salvage situations where primary and second-line treatments have been unsatisfactory, prescribers look for sophisticated bio-implant modalities that reflect intricate therapeutic solutions and advanced technological sophistication. They prioritize reliability, internationally acclaimed clinical evidence, and higher order material composition.
Examples:
Orthopedic Revision Surgery: Implants made from advanced alloys (Cobalt-Chromium alloys in Exactech or Zimmer Biomet revision implants) are preferred because of their mechanical strength and structural integrity.
Cardiovascular: Transcatheter valves (such as Edwards Lifesciences' SAPIEN valves or Medtronic's CoreValve) prevail in salvage treatment when previous valves and interventions have failed.
Preferred Adjunctive Medications at this Stage:
Immunosuppressants (such as prednisone or azathioprine), closely monitored anticoagulants (warfarin/Coumadin) and powerful analgesics (hydromorphone/Dilaudid) are strictly added to control immune responses, excessive clotting risks, and intense postoperative pain in these complex cases.
Disease Stages Influencing Prescribers' Choices
Apart from treatment lines, disease stage also determines physician choice for bio-implants. Physicians discriminate their implant selection distinctly based on three broad categories of disease complexity stages: Early, Intermediate, and Advanced stage conditions.
Early-stage diseases: Physicians opt for less invasive implants such as biodegradable stents (Abbott's Absorb GT1 bioresorbable vascular scaffold preferred at early plaque build-up).
Intermediate-stage diseases: The move to more robust materials like permanent stents (Medtronic's Resolute Integrity or Abbott's XIENCE Sierra) is in vascular situations where there is moderate plaque buildup.
Advanced-stage diseases: Choice moves to robust implants offering structural solutions and long-term survival ('last-resort' implants), i.e., mechanical heart valves (Sorin Carbomedics or Abbott's Masters Valve) or hip replacements like Zimmer Biomet's Taperloc and Stryker's Exeter.
Other Influencing Factors Affecting Prescriber Preferences
A number of other issues have an important impact on bio-implant prescribing, which should also be taken into account:
Clinical Efficacy and Evidence-based Outcomes: Clinicians select products with robust clinical evidence from published clinical trials. Similar positive patient outcome data serves to distinguish high-end products over more generic or elemental equivalents.
Patient's Comorbidities and Patient-Derived Preferences: The prescriber will often analyze the patient's personal preference, age, activity level, co-morbidities, and subsequent QoL prognosis prior to advising on a particular bio-implant or attendant pharmaceutical regimen.
Global Bio-implant Market insights, by product type
By Product Type, the market is segmented into cardiovascular implants, dental implants, spinal bio-implants, orthopedic implants, ophthalmic implants, and others. Out of which, cardiovascular implants segment is expected to dominate the global bio-implant market during the forecast period, owing to increasing research and development to develop novel cardiac implant products.
For instance, in February 2025, Abbott, a medical device company, announced the world's first patient implant of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinicalstudy. The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology, and is the first to occur around the world within the pivotal trial.
Global Bio-implant Market insights, by material type
By Material Type, the market is segmented into Biomaterial Metal, Ceramic, Alloys, and Polymer. Out of which, the ceramic segment is expected to hold second largest share in market over the forecast period, owing to increasing ceramic product approvals by the regulatory bodies.
For instance, in December 2021, DentalPoint, the pioneer in two-piece ceramic implants, announced that it has received U.S. FDA approval for its latest productnamed ZERAMEX XT. ZERAMEX XT is a 100 % metal-free alternative to titanium implants that is designed for highly cosmetic tooth replacement, especially in the esthetic zone.
Global Bio-implant Market insights, by End User
By End User, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others. Out of which, hospitals and clinics segment is expected to dominate the market over the forecast period. For Instance, in July 2021, Duke University Hospital, announced that a surgical team has successfully implanted a new-generation artificial heart in a 39-year-old man with heart failure, and thus, become the first center in North America to perform the procedure.
Global Bio-implant Market- Cross Sectional Analysis
In the product type, cardiovascular implants segment holds a dominant position in the Europe region due to increasing research and development activities by key market players. For instance, in February, 2022, Abbott, announced the world's first patient implant of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study. The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology, and is the first to occur around the world within the pivotal trial.
North America Bio-implant Market Analysis and Trends
North America is expected to dominate the global bio-implant market over the forecast period, owing to North America 35.10% market share. High prevalence of cardiovascular diseases such as coronary heart disease, ischemic heart disease, arrhythmias, and others is expected to drive North America bio-implant market growth.
For instance, according to an article published by Circulation Journal, a peer reviewed open access journal, in January 2021, the prevalence of cardiovascular diseases in adults above age of 20 years, in U.S., is around 49.2% (126.9 million in 2018), and increases with age in both males and females. The same source stated that the incidence of valvular heart disease is around 64 per 100, 000 person-years, with aortic stenosis (47.2%), mitral regurgitation (24.2%), and aortic regurgitation (18.0%) contributing most of the valvular diagnoses in 2018, in U.S.
Global Bio-implant Market Dominating Countries
United States Bio-implant Market Analysis and Trend
The U.S. dominates the world bio-implant market with robust healthcare infrastructure, early technology adoption of sophisticated medical devices, and widespread chronic and degenerative disease prevalence. Key industry giants such as Medtronic, Boston Scientific, and Zimmer Biomet have their headquarters here, which promotes ongoing innovation and FDA-approved product pipelines. Pervasive insurance coverage and R&D investments power further market growth.
Germany Bio-implant Market Analysis and Trend
Germany leads the European bio-implant market because of its strong medical device manufacturing base and stringent focus on quality and regulatory compliance. It is a center for orthopedic and dental implants, fueled by well-capitalized public healthcare systems and elderly populations. Players like B. Braun and Ottobock make significant contributions to exports and innovation.
Japan Bio-implant Market Analysis and Trend
Japan is a significant power in the Asia-Pacific region, with an increasingly aging population and strong demand for orthopedic, cardiovascular, and ophthalmic implants. Government policies aimed at encouraging minimally invasive procedures and powerful domestic manufacturers such as Terumo and Nipro are enhancing the nation's competitiveness on the global stage in bio-implants.
India Bio-implant Market Analysis and Trend
India is becoming a rising power in the bio-implant sector, driven by expanding healthcare access, medical tourism, and affordable production. Local entrepreneurship and partnerships with multinational companies are on the rise, especially for dental and orthopedic implants. Still, affordability and regulatory simplification remain major issues for high-end implant technologies.
Market Report Scope
Surface Vision And Inspection Market Report Coverage
Report Coverage
Details
Base Year:
2024
Market Size in 2025:
USD 102.41 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
6%
2032 Value Projection:
USD 153.99 Bn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa
In May 2024, Zimmer Biomet entered into an acquisition agreement for OSSIS, a business focused on custom orthopedic implants manufactured by 3D printing, specifically for sophisticated hip and pelvic reconstructions. This acquisition expands Zimmer Biomet's stature in the personalized orthopedic implant market and underscores the increasing popularity of patient-specific bio-implant solutions.
In June 2025, CollPlant Biotechnologies, an Israeli regenerative medicines company, successfully 3D-bioprinted commercial-size breast implants with its own proprietary recombinant human collagen (rhCollagen). This represents a significant development in sustainable, biocompatible, and animal-free implant technologies.
Analyst View
The bio-implant segment is experiencing high growth, led mainly by increasing incidence of chronic illnesses and growing demand for minimally invasive treatments. Developments in biomaterials, such as biodegradable and bioresorbable implant materials, are generating promising opportunities, enabling producers to provide enhanced patient outcomes and compatibility. Similarly, the growing world geriatric population majorly supports overall market forces, as elderly populations are more prone to ailments that call for orthopedic or cardiovascular implants. Additionally, increased uptake of bio-implants through enhanced patient awareness and enhanced healthcare infrastructure further fuels market take-up.
Nevertheless, some restraints do present challenges to consistent growth. They are rigid regulatory systems within developed economies, which may hinder new innovations' entry. Prohibitive cost of implantation, along with reimbursement policy uncertainties in the developing markets, also serve as market barriers.
North America leads the bio-implant market, driven by strong healthcare infrastructure, high technology uptake within healthcare modalities, and a significantly aging population base. On the other hand, the Asia-Pacific region offers the most rapid growth opportunities, fueled by fast development in healthcare infrastructure, increasing medical tourism industry, and increasing disposable incomes in nations like China, India, and South Korea.
Market Segmentation
Global Bio-implant Market, By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
Global Bio-implant Market, By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
Global Bio-implant Market, By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
Global Bio-implant Market, By Region
North America
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country
U.S.
Canada
Latin America
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Cardiovascular Implants
Dental Implants
Spinal Bio-implants
Orthopedic Implants
Ophthalmic Implants
Others
By Material Type
Biomaterial Metal
Ceramic
Alloys
Polymer
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Abbott.
Dentsply Sirona Plc.
Medtronic
Stryker Corporation
Zimmer Biomet
B. Braun
Cook Medical
C. R. Bard
Edwards Lifesciences
Wright Medical Technology
Boston Scientific Corporation
Sources
Primary Research Interviews
Senior Executives from Leading Bio-implant Manufacturers
Researchers from Bio-medical Institutions
Orthopedic Surgeons and Healthcare Professionals
Industry Consultants and Market Analysts
Others
Databases
World Health Organization (WHO) Database
Centers for Disease Control and Prevention (CDC) Database
Food and Drug Administration (FDA) Database
Others
Magazines
Medical Device and Diagnostic Industry (MD&DI) Magazine
Orthopedic Design & Technology Magazine
Biotechnology Magazine
Healthcare Global Magazine
Others
Journals
International Journal of Biomaterials
Journal of Biomedical Materials Research
Journal of Orthopaedic Research
Others
Newspapers
The New York Times (Health Section)
The Guardian (Medical News Section)
Business Standard (Pharmaceutical and Healthcare Section)
Financial Times (Healthcare Section)
Others
Associations
American Academy of Orthopaedic Surgeons (AAOS)
Orthopaedic Research Society (ORS)
International Society for Biomaterials (ISB)
American Association of Tissue Banks (AATB)
Others
Public Domain Sources
U.S. National Library of Medicine (ClinicalTrials.gov)
European Medicines Agency (EMA)
National Institutes of Health (NIH)
Organization for Economic Co-operation and Development (OECD) Health Database
Others
Proprietary Elements
CMI Data Analytics Tool
Proprietary CMI Existing Repository of information for last 8 years
*Definition: Bio-implants are prosthesis or artificial medical devices that replace missing tissues, and supports a damaged biological structure to improve biological functions of the body, and are made up of material obtained of human or animal origin or biosynthetic materials. Bio-implant is used to assist and regularize human physiological functions.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
The Bio-implant Market size is estimated to be valued at USD 102.41 Bn in 2025, and is expected to reach USD 153.99 Bn by 2032.
The CAGR of the global Market is projected to be 6% from 2025 to 2032.
Increasing adoption of inorganic growth strategies such as collaborations and partnerships by key players in the market, increasing product launches and increasing product approvals from regulatory bodies are expected to drive the market growth.
Cardiovascular implants segment is the leading product type segment in the market.
The major factors that can hamper growth of the market include product recalls from the regulatory authorities.
Major players operating in the market include Abbott., Dentsply Sirona Plc., Medtronic, Stryker Corporation, Zimmer Biomet, B.Braun, Cook Medical, C.R. Bard, Edwards Lifesciences, Wright Medical Technology, and Boston Scientific Corporation.
Schedule a meeting with report Author
